PROFUSA INC (PFSA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.72+3.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · PFSA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute the Option Agreement to acquire G3 Vision Labs and integrate its diagnostics business to operate as a public diagnostics company with recurring revenues.
Stated as a priority in 3 distinct disclosures including 2026-Q1 and 2026-Q2. Management is progressing on executing the Option Agreement to acquire G3 Vision Labs, a commercial-stage diagnostics company with estimated 2025 net revenues of $111 million. Stockholders’ equity is expected to improve to $28.4 million by July 31, 2026 due to the transaction. The trajectory shows delivering progress toward acquisition and integration.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs”
“Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs”
“Profusa Inc. proposes to acquire the Bio Insights LLC PanOmics assets for $30 million”
Meet Nasdaq minimum listing requirements including reverse stock split and shareholder approvals to maintain listing status.
Management stated Nasdaq listing compliance as a priority in 3 disclosures including 2026-Q1 and 2026-Q2. The 4:1 reverse stock split effective August 18, 2026, and progress on the Option Agreement have supported meeting Nasdaq minimum listing requirements. The company is delivering on regulatory milestones to maintain listing status.
“The impact of the Profusa 4:1 reverse stock split and executing the Option Agreement have been supportive of meeting Nasdaq’s minimum listing requirements.”
“No suspension or removal from listing of Profusa’s common stock on Nasdaq shall have occurred as a condition to the Option Agreement.”
“Profusa shall hold a meeting of its shareholders for voting upon issuance of Closing Shares prior to June 30, 2026.”
Execute debt-to-equity exchanges, raise financing, and manage working capital to support operations and acquisitions.
Management stated financial obligations and capital allocation as a priority in 3 disclosures including 2026-Q1 and 2026-Q2. Debt holders executed $10.7 million in convertible exchange agreements, and Profusa borrowed $650,000 for working capital. The company expects to raise $7 million in convertible note financing. The trajectory shows delivering progress on capital management.
“Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements.”
“Profusa borrowed $650,000 under its current note agreement to fund near-term working capital needs.”
“Profusa expects to close on approximately $7 million of necessary financing in the form of a convertible note.”
Acquire Bio Insights PanOmics assets for $30 million and allocate funds for assay validation and capital equipment.
Newly stated in 2026-Q1. Management proposed acquiring Bio Insights PanOmics assets for $30 million with plans to allocate funds for assay validation and capital equipment. No subsequent disclosures confirm completion or progress, so delivery status is limited to initial announcement.
“Profusa Inc. proposes to acquire the Bio Insights LLC PanOmics assets for $30 million.”
Ensure compliance with Nasdaq listing rules including bid price and stockholders' equity requirements to maintain listing on The Nasdaq Capital Market.
Over the trailing year it converted 0.69x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
51 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.